Business Description
Zhejiang Cheng Yi Pharmaceutical Co Ltd
ISIN : CNE100002YC7
Share Class Description:
SHSE:603811: ACompare
Compare
Traded in other countries / regions
603811.China IPO Date
2017-03-15Description
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.67 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | 1.58 | |||||
| Interest Coverage | 12.65 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.23 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year EPS without NRI Growth Rate | 0.8 | |||||
| 3-Year FCF Growth Rate | 53.5 | |||||
| 3-Year Book Growth Rate | 10.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.57 | |||||
| 9-Day RSI | 35.13 | |||||
| 14-Day RSI | 41.1 | |||||
| 6-1 Month Momentum % | 21.37 | |||||
| 12-1 Month Momentum % | -23.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.6 | |||||
| Days Inventory | 194.52 | |||||
| Days Sales Outstanding | 28.83 | |||||
| Days Payable | 127.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.56 | |||||
| Dividend Payout Ratio | 0.38 | |||||
| 3-Year Dividend Growth Rate | 19.6 | |||||
| Forward Dividend Yield % | 2.56 | |||||
| 5-Year Yield-on-Cost % | 5.91 | |||||
| Shareholder Yield % | 5.58 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.89 | |||||
| Operating Margin % | 21.65 | |||||
| Net Margin % | 22.66 | |||||
| FCF Margin % | 14.24 | |||||
| ROE % | 13.82 | |||||
| ROA % | 9 | |||||
| ROIC % | 9.22 | |||||
| ROC (Joel Greenblatt) % | 20.1 | |||||
| ROCE % | 13.28 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.45 | |||||
| PE Ratio without NRI | 15.15 | |||||
| Shiller PE Ratio | 18.33 | |||||
| Price-to-Owner-Earnings | 55.49 | |||||
| PEG Ratio | 1.12 | |||||
| PS Ratio | 3.59 | |||||
| PB Ratio | 2.07 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| Price-to-Free-Cash-Flow | 24.81 | |||||
| Price-to-Operating-Cash-Flow | 14.75 | |||||
| EV-to-EBIT | 13.43 | |||||
| EV-to-EBITDA | 13.43 | |||||
| EV-to-Revenue | 3.63 | |||||
| EV-to-FCF | 27.13 | |||||
| Price-to-Projected-FCF | 2.35 | |||||
| Price-to-DCF (Earnings Based) | 0.91 | |||||
| Price-to-DCF (FCF Based) | 0.79 | |||||
| Price-to-Graham-Number | 1.22 | |||||
| Earnings Yield (Greenblatt) % | 7.45 | |||||
| FCF Yield % | 4.09 | |||||
| Forward Rate of Return (Yacktman) % | 1.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zhejiang Cheng Yi Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 732.681 | ||
| EPS (TTM) (Â¥) | 0.51 | ||
| Beta | 1.03 | ||
| Volatility % | 40.35 | ||
| 14-Day RSI | 41.1 | ||
| 14-Day ATR (Â¥) | 0.230044 | ||
| 20-Day SMA (Â¥) | 8.1675 | ||
| 12-1 Month Momentum % | -23.35 | ||
| 52-Week Range (Â¥) | 5.78 - 10.62 | ||
| Shares Outstanding (Mil) | 327.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zhejiang Cheng Yi Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zhejiang Cheng Yi Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zhejiang Cheng Yi Pharmaceutical Co Ltd Frequently Asked Questions
What is Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811)'s stock price today?
The current price of SHSE:603811 is ¥7.88. The 52 week high of SHSE:603811 is ¥10.62 and 52 week low is ¥5.78.
When is next earnings date of Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811)?
The next earnings date of Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811) is .
Does Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811) pay dividends? If so, how much?
The Dividend Yield %  of Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811) is 2.56% (As of Today), Highest Dividend Payout Ratio of Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811) was 0.53. The lowest was 0.3. And the median was 0.37. The  Forward Dividend Yield % of Zhejiang Cheng Yi Pharmaceutical Co Ltd(SHSE:603811) is 2.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers